|
Authors | Study design | Number of patients | Number of metastases in each patient | Primary organ | Dose/fractionation | Followup (months) | Outcomes | Toxicity |
|
Okunieff et al. [20] | Retrospective | 42 | 1 to 5 | NA | 50 Gy/5 fr (isocenter) | 4–61 (median 15) | Crude LC: 94% MS: 23.4 months | Grade 3 (pleural effusion): 1 |
Kavanagh et al. [36] | Retrospective | 34 | 1 or 2 | Lung 15, Colorectal: 9 Others 10 | 48–60 Gy/4-5 fr (isocenter) | 10–80 (median, 27) | 2-year LC: 90% 2-year OS: 84.3% | Grade 3 pneumonitis: 3 |
Nagata et al. [37] | Retrospective | 84 | 1 to 3 | Lung 32, Colorectal 11, Kidney 7, others 34 | 26–48 Gy/1–8 fr (covering PTV) | 14–80 (median, 17) | 3-year LC: 82% 3-year OS: 16% | NA |
Norihisa et al. [38] | Prospective | 41 | 1 or 2 | Lung 5, Breast 4, Kidney 4, Others 14 | 26–37.5 Gy/1–3 fr | 2–37 (median, 9) | 2-year LC: 80% 2-year OS: 33% | No grade 3, 4 |
Ernst-Stecken et al. [42] | Prospective | 61 | 1 or 2 | Lung 31, Colorectal 8, Others 22 | 12–30 Gy/fr (isocenter) | 2–82 (median, 14) | 2-year LC: 74% 2-year OS: 65% | Grade 3 pneumonitis: 3% |
Hof et al. [44] | Prospective | 38 | 1 to 3 | Colorectal 9, Sarcoma 7, Kidney 7, others 15 | 48–60 Gy/3 fr (covering PTV) | 6–48 (median, 16) | 2-year LC: 96% MS: 19 months | Grade 3 pneumonitis: 4 Grade 3 chest wall: 2 |
|